Milestone Pharmaceuticals Statistics
Share Statistics
Milestone Pharmaceuticals has 53.33M shares outstanding. The number of shares has increased by 59.09% in one year.
| Shares Outstanding | 53.33M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.02% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 50.59M |
| Failed to Deliver (FTD) Shares | 36.67K |
| FTD / Avg. Volume | 11.64% |
Short Selling Information
The latest short interest is 454.79K, so 0.85% of the outstanding shares have been sold short.
| Short Interest | 454.79K |
| Short % of Shares Out | 0.85% |
| Short % of Float | 0.9% |
| Short Ratio (days to cover) | 2.46 |
Valuation Ratios
The PE ratio is -1.2 and the forward PE ratio is -2.17.
| PE Ratio | -1.2 |
| Forward PE | -2.17 |
| PS Ratio | 71.74 |
| Forward PS | 19.1 |
| PB Ratio | 4.28 |
| P/FCF Ratio | -1.54 |
| PEG Ratio | n/a |
Enterprise Valuation
Milestone Pharmaceuticals Inc. has an Enterprise Value (EV) of 109.75M.
| EV / Earnings | -1.84 |
| EV / Sales | 109.75 |
| EV / EBITDA | -1.93 |
| EV / EBIT | -1.8 |
| EV / FCF | -2.36 |
Financial Position
The company has a current ratio of 10.11, with a Debt / Equity ratio of 3.
| Current Ratio | 10.11 |
| Quick Ratio | 10.11 |
| Debt / Equity | 3 |
| Total Debt / Capitalization | 75 |
| Cash Flow / Debt | -0.92 |
| Interest Coverage | -23.92 |
Financial Efficiency
Return on equity (ROE) is -3.56% and return on capital (ROIC) is -89.13%.
| Return on Equity (ROE) | -3.56% |
| Return on Assets (ROA) | -0.79% |
| Return on Capital (ROIC) | -89.13% |
| Revenue Per Employee | 21.28K |
| Profits Per Employee | -1.27M |
| Employee Count | 47 |
| Asset Turnover | 0.01 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -31.42% in the last 52 weeks. The beta is 1.73, so Milestone Pharmaceuticals 's price volatility has been higher than the market average.
| Beta | 1.73 |
| 52-Week Price Change | -31.42% |
| 50-Day Moving Average | 1.68 |
| 200-Day Moving Average | 1.57 |
| Relative Strength Index (RSI) | 48.98 |
| Average Volume (20 Days) | 315.11K |
Income Statement
In the last 12 months, Milestone Pharmaceuticals had revenue of $1.00M and earned -$59.69M in profits. Earnings per share was $-1.39.
| Revenue | 1.00M |
| Gross Profit | 1.00M |
| Operating Income | -61.10M |
| Net Income | -59.69M |
| EBITDA | -56.84M |
| EBIT | -61.10M |
| Earnings Per Share (EPS) | -1.39 |
Balance Sheet
The company has $13.76M in cash and $51.77M in debt, giving a net cash position of -$38.02M.
| Cash & Cash Equivalents | 13.76M |
| Total Debt | 51.77M |
| Net Cash | -38.02M |
| Retained Earnings | -326.03M |
| Total Assets | 82.71M |
| Working Capital | 75.73M |
Cash Flow
In the last 12 months, operating cash flow was -$46.42M and capital expenditures -$112.00K, giving a free cash flow of -$46.54M.
| Operating Cash Flow | -46.42M |
| Capital Expenditures | -112.00K |
| Free Cash Flow | -46.54M |
| FCF Per Share | -1.08 |
Margins
Gross margin is 100%, with operating and profit margins of -6.11K% and -5.97K%.
| Gross Margin | 100% |
| Operating Margin | -6.11K% |
| Pretax Margin | -5.97K% |
| Profit Margin | -5.97K% |
| EBITDA Margin | -5.68K% |
| EBIT Margin | -6.11K% |
| FCF Margin | -4.65K% |
Dividends & Yields
MIST does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -77.65% |
| FCF Yield | -48.61% |
Analyst Forecast
The average price target for MIST is $9, which is 402.8% higher than the current price. The consensus rating is "Buy".
| Price Target | $9 |
| Price Target Difference | 402.8% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
Scores
| Altman Z-Score | -5.48 |
| Piotroski F-Score | 2 |